Targovax ASA announces the appointment of two new Board Directors
Oslo, Norway, 21 April 2022 - Targovax ASA (OSE: TRVX) announces that the General Meeting has elected Dr Raphael Clynes and Mr Thomas Falck as new members of its Board of Directors.Dr ClynesDr Clynes is an internationally recognized cellular immunologist and medical oncologist. Dr Clynes was on the faculty at the Columbia University where he developed several novel therapeutic approaches in cancer and autoimmunity. Since joining industry in 2014, Dr Clynes has led clinical immunotherapy development, including checkpoint inhibtors and novel CD3 bispecifics, at Bristol Myers Squibb (BMS)